JAK inhibition for CD3

Humans Prednisone / therapeutic use Prospective Studies CD3 Complex Hypereosinophilic Syndrome / drug therapy CD4-Positive T-Lymphocytes
Hypereosinophilic syndrome JAK inhibition Lymphocytic variant Ruxolitinib T-cell clone

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
06 2023
Historique:
received: 24 01 2023
accepted: 27 02 2023
medline: 23 5 2023
pubmed: 5 3 2023
entrez: 4 3 2023
Statut: ppublish

Résumé

Alternatives are urgently needed in patients with CD3

Identifiants

DOI: 10.1016/j.clim.2023.109275 PMID: 36870379
pubmed: 36870379
pii: S1521-6616(23)00054-2
doi: 10.1016/j.clim.2023.109275
pii:
doi:

Substances chimiques

ruxolitinib 82S8X8XX8H
Prednisone VB0R961HZT
CD3 Complex 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109275

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Stanislas Faguer (S)

Department of Nephrology and Organ transplantation, National Reference Center for Rare Kidney Diseases, University Hospital of Toulouse & INSERM U1297 (I2MC), F-31000 Toulouse, France; Faculty of Medicine, University Toulouse 3, F-31000 Toulouse, France. Electronic address: stanislas.faguer@inserm.fr.

Matthieu Groh (M)

National Reference Center for Hypereosinophilic Syndromes, CEREO, France; Department of Internal Medicine, Hôpital Foch, Suresnes, France.

François Vergez (F)

Laboratory of Immuno-Hematology, Cancer University Institute of Toulouse - Oncopole, University Hospital of Toulouse, F-31000 Toulouse, France.

Mathilde Hunault-Berger (M)

Department of Hematology, University Hospital of Anger, Angers, France.

Nicolas Duployez (N)

National Reference Center for Hypereosinophilic Syndromes, CEREO, France; Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France.

Yves Renaudineau (Y)

Laboratory of Immunology, University Hospital of Toulouse, INSERM U1291, CNRS U5051, F-31000 Toulouse, France.

Carle Paul (C)

Department of Dermatology, University Hospital of Toulouse, F-31000 Toulouse, France.

Guillaume Lefevre (G)

National Reference Center for Hypereosinophilic Syndromes, CEREO, France; CHU Lille, Institut d'Immunologie & University of Lille, Inserm U995 - LIRIC - Lille Inflammation Research International Center, Lille, France.

Jean-Emmanuel Kahn (JE)

National Reference Center for Hypereosinophilic Syndromes, CEREO, France; Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine, Ambroise Paré Hospital, F-92100 Boulogne-Billancourt, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › JAK inhibition for CD3
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènediols › Prednisone › JAK inhibition for CD3
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › JAK inhibition for CD3
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigènes CD3 › JAK inhibition for CD3
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Troubles leucocytaires › Éosinophilie › Syndrome hyperéosinophilique › JAK inhibition for CD3
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › JAK inhibition for CD3